Biomarkers of multimorbidity: A systematic review
Ageing Research Reviews · 2025-12 · 112 · 102870
DOI: 10.1016/j.arr.2025.102870 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Ageing Research Reviews, 2025-12. Verfasst von Maria Beatrice Zazzara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Aging, Orthopaedics and Rheumatological Sciences, Università Cattol…. Hauptthemen laut MEDLINE: Biomarkers, Multimorbidity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Swedish Research Council.
Abstract (Originalsprache)
The development of multiple chronic diseases in the same individual (i.e., multimorbidity) results from the loss of homeostasis across several biological systems. Identifying pathophysiological pathways common to multiple diseases, using accessible biomarkers, could increase our understanding of multimorbidity and improve its prognostication and management. We conducted a systematic review of peer-reviewed articles published till September 2024 that investigated biomarkers of multimorbidity. Due to study heterogeneity, a synthesis without meta-analysis was performed on 43 studies employing harvest plots based on direction of effect, sample size and study quality. Findings highlight how inflammatory and metabolic biomarkers, such as interleukin-6 (IL-6) and glycated haemoglobin (HbA1c) especially, but also triglycerides, low-density lipoprotein (LDL) cholesterol and kidney and liver markers, along with markers of neurodegeneration including Neurofilament Light Chain (NfL) and Phospho-Tau 217 (p-tau 217), were directly associated with multimorbidity. Nonetheless, evidence for hormonal and vascular activation markers, as well as more novel geroscience biomarkers, remains limited. These markers could have a key role in identifying individuals at high risk of developing or worsening multimorbidity. The review also highlights how methodological challenges, including heterogeneity in study design, populations, and multimorbidity definitions, impact on comparability and generalizability of findings. Addressing these gaps through standardized, longitudinal studies and multi-omics approaches is crucial to improve our understanding of the pathophysiological mechanisms of multimorbidity. In summary, this review outlines the independent association of diverse biomarkers with multimorbidity, opening to the possibility of identifying specific pathophysiological pathways for risk stratification and possible target of future personalized interventions. • Multimorbidity research has focused mainly on inflammatory and metabolic biomarkers. • IL-6, HbA1c and NfL emerged as key biomarkers associated with multimorbidity. • Neurodegeneration markers (i.e. NfL and p-tau 217) show potential for risk stratification of persons with multimorbidity. • Knowledge gaps and methodological challenges hinder advancement in multimorbidity research. • Multi-omics and longitudinal studies should be implemented to fill these gaps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Aging, Orthopaedics and Rheumatological Sciences, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: mariabeatricezaz…
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet Stockholm University, Sweden.
- Section of Neurology, Italian National Research Center on Aging (IRCCS INRCA), Ancona, Italy.
- Laboratory of Pharmacoepidemiology and Biostatistics, Italian National Research Center on Aging (IRCCS INRCA), Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, CS, Italy.
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet Stockholm University, Sweden; Stockholm Gerontology Research Center, Stockholm, Sweden.
Förderung
- European Commission
- Swedish Research Council
Zitieren
APA
Zazzara, M. B., Triolo, F., Biscetti, L., Paparazzo, E., Fiorillo, M., Vetrano, D. L., Onder, G., & BIO-SIGN Study Investigators (2025). Biomarkers of multimorbidity: A systematic review. Ageing Research Reviews, 112, 102870. https://doi.org/10.1016/j.arr.2025.102870
Vancouver
Zazzara MB, Triolo F, Biscetti L, Paparazzo E, Fiorillo M, Vetrano DL, et al. Biomarkers of multimorbidity: A systematic review. Ageing Research Reviews. 2025;112:102870. doi:10.1016/j.arr.2025.102870
BibTeX
@article{Zazzara2025,
author = {Zazzara, Maria Beatrice and Triolo, Federico and Biscetti, Leonardo and Paparazzo, Ersilia and Fiorillo, Marco and Vetrano, Davide Liborio and Onder, Graziano and BIO-SIGN Study Investigators, BIO-SIGN Study Investigators},
title = {Biomarkers of multimorbidity: A systematic review},
journal = {Ageing Research Reviews},
year = {2025},
volume = {112},
pages = {102870},
doi = {10.1016/j.arr.2025.102870}
}
EUVIMED